2.1
Vutrisiran (Amvuttra, Alnylam Pharmaceuticals) is indicated for the 'treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR‑CM)'.
2 Information about vutrisiran
Marketing authorisation indication
Dosage in the marketing authorisation
2.2
The dosage schedule is available in the summary of product characteristics for vutrisiran.
Price
2.3
The list price of vutrisiran is £95,862.36 per 25‑mg pre-filled syringe.
2.4
The company has a commercial arrangement. This makes vutrisiran available to the NHS with a discount. The size of the discount is commercial in confidence.
Carbon Reduction Plan
2.5
For information, Alnylam did not disclose its Carbon Reduction Plan for UK carbon emissions.